DURHAM, N.C., Oct. 8 /PRNewswire/ -- Argos Therapeutics today announced that Jeff Abbey, the company's president and chief executive officer, will present recent clinical developments and a corporate overview at the 18th Annual BioPartnering Europe conference in London at 12:15 p.m. BST on Monday, Oct. 11, 2010. The conference will take place at the Queen Elizabeth II Conference Centre.
Argos recently presented favorable progression-free survival and safety results from an ongoing Phase 2 trial for its Arcelis immunotherapy for renal cell carcinoma, AGS-003, in combination with sunitinib. The company anticipates the initiation of a large, randomized and controlled clinical study for AGS-003 in combination with sunitinib in 2011.
About the Arcelis™ Technology
Arcelis is Argos' proprietary technology for personalizing RNA-loaded dendritic cell immunotherapies for cancer, HIV and other infectious diseases. This platform is based on optimizing a patient's own (autologous) dendritic cells to trigger a tumor- or pathogen-specific immune response. To address the challenge of the unique genetic profile of each patient's disease and the genetic mutations of that disease, Argos loads the autologous dendritic cells with a sample of messenger RNA isolated from the patient's disease. Through this process, dendritic cells can potentially prime immune responses to the entire antigenic repertoire, resulting in an immunotherapeutic that is customized to the patient's specific disease.
About Argos Therapeutics, Inc.Argos is an immunotherapy company developing new treatments for cancer, infectious and autoimmune diseases and transplantation rejection. The Company has generated multiple platform technologies and a diverse pipeline of products based on its expertise in the biology of dendritic cells — the master switch that turns the immune system on or off. www.argostherapeutics.comContacts:David Schull or Andreas MarathovouniotisRusso Partners LLC(212) 845-4271 or (212) firstname.lastname@example.org or email@example.comJeff AbbeyArgos Therapeutics(919) firstname.lastname@example.org
|SOURCE Argos Therapeutics, Inc.|
Copyright©2010 PR Newswire.
All rights reserved